SAN DIEGO-First-degree relatives of colorectal cancer patients are at increased risk of getting the disease themselves, and it is generally recommended that they have colorectal cancer screening beginning at age 40. A new study suggests that educational interventions by phone and mail may increase screening rates in this high-risk population.
SAN DIEGOFirst-degree relatives of colorectal cancer patients are at increased risk of getting the disease themselves, and it is generally recommended that they have colorectal cancer screening beginning at age 40. A new study suggests that educational interventions by phone and mail may increase screening rates in this high-risk population.
Surprisingly, first-degree relatives of colon cancer patients often underestimate the risks, particularly lower-income patients and those whose affected relatives are older, said Dennis J. Ahnen, MD, professor of gastroenterology, University of Colorado.
Dr. Ahnen presented results of an interventional study at an American Gastroenterological Association research forum held during the Digestive Disease Week conference.
Our aim was to design, implement, and evaluate a brief, telephone-based educational and counseling intervention to promote cancer screening for this group, he said.
Physicians from more than 30 hospitals across the United States gave permission for the researchers to contact their patients with colorectal cancer. After the patient gave informed consent, a telephone interview was conducted to obtain a list of eligible first-degree relativesmen and women 50 years and older who were English speaking, aware of the cancer diagnosis of the family member, and had no personal history of cancer.
Families with more than one eligible first-degree relative were randomized to intervention or control groups. Consenting first-degree relatives were sent an introductory letter, a brochure, and a core baseline computer-assisted telephone interview that measured colon cancer attitudes, beliefs, risk perceptions, and screening practices.
The intervention group, Dr. Ahnen said, also received a brief, tailored, motivational telephone barriers counseling module designed to encourage colorectal cancer screening, as well as a tailored, reinforcement mail-out. We followed up with both groups after 3 and 12 months, he said.
The researchers conducted 860 co-lorectal cancer patient interviews, which yielded 2,069 first-degree relatives. Of those, 1,266 completed the baseline interview (38% men and 62% women). So far, Dr. Ahnen reported, 969 first-degree relatives have completed the 3-month interview and 599 the 12-month interview.
The study population is predominately white (84%), well educated (67% with some college or more), and affluent (63% earn $40,000 a year or more).
At baseline, Dr. Ahnen said, 45% of the participants reported colorectal screening within the recommended guidelines (fecal occult blood tests within 1 year or endoscopic screening within the past 5 years). At the most recent analysis, the rate of adherence to the guidelines had increased to 72% in the intervention group and 57% in the control group.
The preliminary results indicate that phone-based education and counseling can significantly improve screening rates in first-degree relatives of colorectal cancer patients, Dr. Ahnen concluded.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma
February 7th 2024Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.